Swiss Business News and Press Releases
Part of the HELP.CH ® Network
Swiss News Now is a news platform with the latest news and information from Swiss companies and Swiss authorities. Latest news from Switzerland in English.
WISeKey Reports First Half 2026 Financial Results, Accelerates Quantum and Post-Quantum Strategy and Provides Outlook
GENEVA, Switzerland – WISeKey International Holding Ltd (“WISeKey” or the “Company”) (SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity, post-quantum semiconductors, quantum technologies and secure satellite infrastructure, today announced its financial results for the six months ended June 30, 2026 (H1 2026) and provided an update on significant strategic developments achieved since the beginning of the year.
Christa Pike taken to hospital after surviving execution, lawyer says | BBC News
Tennessee death row inmate Christa Pike has been taken to hospital after she was still alive following two lethal injections during her execution, her lawyer says.
Leclanché Announces Further Delay in Publishing its 2025 Annual Report
YVERDON-LES-BAINS, Switzerland – Leclanché SA (SIX: LECN) (“Leclanché” or the “Company“) one of the world‘s leading energy storage companies, announces a further delay in the publication of its 2025 Annual Report and that it could not publish the 2025 Annual Report by 30 September 2026.
Sika closes acquisitions of Akkim - accelerating global expansion in adhesives and sealants
Sika has closed the acquisition of Akkim, a leading global manufacturer of adhesives and sealants based in Turkey. The acquisition further strengthens Sika’s position in the adhesives and sealants industry and creates substantial growth opportunities through expanded distribution and geographic reach as well as enhanced manufacturing capacity.
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
Pratteln, Switzerland – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2026.
Ascom reports significant increase in order intake in the first half of 2026 and improved profitability
Ascom reports continued progress in the first half of 2026, with higher incoming orders, an increased order backlog and improved profitability on EBITDA, EBIT and Group profit level. Net revenue increased at constant currencies by 2.6% and remained broadly stable at actual currencies. Ascom confirms its 2026 guidance of low to mid-single-digit revenue growth at constant currencies and an EBITDA margin of 10–12%.
Avolta extends long-term travel retail contracts across four Mexican airports
Avolta AG (SIX: AVOL) has further strengthened its partnership with Grupo Aeroportuario del Pacífico (GAP) through long-term travel retail contract extensions across Guadalajara, Puerto Vallarta, Los Cabos and Bajío International Airports in Mexico.
Richemont announces the appointment of a Non-executive Co-Deputy Chairman of its Board of Directors
The Board of Compagnie Financière Richemont SA ('Richemont') appoints Mr Anton Rupert as Non-executive Co-Deputy Chairman of the Board, serving alongside Mr Bram Schot, Non-executive Co-Deputy Chairman.
Medacta Group SA reports above-market revenue growth of 9.7% in constant currency1 with a robust adjus
Medacta Group SA reported above-market revenue growth of 9.7% in constant currency in the first half of 2026, with revenue reaching EUR 368 million. Adjusted EBITDA amounted to EUR 97 million, corresponding to a robust adjusted EBITDA margin of 27.8% in constant currency. The company continued to invest in its growth expansion and confirmed both its outlook for 2026 and its mid-term targets.
BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
BV100 RIV-TARGET, the global Phase 3 registration trial in hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), is actively recruiting following the First Patient First Visit (FPFV) reported in April 2026. The open-label Phase 2b BV100 RIV-CARE trial is scheduled to initiate its first sites in September 2026 in collaboration with ADVANCE-ID. For Alpibectir, the FPFV for the Phase 2b/c pulmonary tuberculosis trial partnered with GSK was reported in March 2026, while the Phase 2 trial in meningeal tuberculosis received its first regulatory approval and is expected to start in the second half of 2026. As of 30 June 2026, the company reported cash and cash equivalents of CHF 69.3 million. Its full-year 2026 guidance was improved, with the expected operating loss reduced to CHF 32–34 million and year-end cash guidance increased to CHF 53 million. Operations are funded into 2028. A conference call is scheduled for today at 2:00 p.m. CET.
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Geneva - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.
A Service by HELP.CH ®
SwissNewsNow.com is a news platform focused on current developments from Switzerland and part of the
HELP.CH ® network.
The platform provides readers with a compact overview of Swiss news, business developments, company information, innovation, technology and society. Selected content is sourced from the HELP.CH news network and related media platforms.
SwissNewsNow.com helps make important Swiss news accessible through structured publication, search engine visibility and distribution across digital channels.
More about the network:
help.swiss/en
The network includes news platforms such as Aktuellenews.ch, HELP.CH News, Swiss-Press.com, Tagesthemen.ch, Aktuellenews.de and Aktuellenews.at. Together they provide coverage of Swiss business, technology, innovation, society and economic developments.
SwissNewsNow.com brings together selected news and information from across the network, providing readers with a convenient gateway to relevant Swiss topics and current developments.